Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating ...

Patient perspectives of prior authorization: Understanding associations with care delivery and delays. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This abstract does ...

3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

The researchers find that in two different cancer types, combining Janus kinase (JAK) inhibitors with checkpoint inhibitor immunotherapy results in better clinical responses in patients with ...

Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...

Please provide your email address to receive an email when new articles are posted on . Adding immune checkpoint inhibitors to neoadjuvant chemotherapy benefited certain patients with early-stage ...